

# Seamless Phase II/III

- Pre-specification!
- Adaptive trials not a panacea
- Lots of up-front work necessary
- Changing endpoints or changing population likely to raise concerns
- Biomarkers may be problematic
- Tradeoff between adaptive Phase II/III and “better” traditional Phase II